TGF-β regulates sclerostin expression via the ECR5 enhancer

Gabriela G. Loots, Hansjoerg Keller, Olivier Leupin, Deepa Murugesh, Nicole M. Collette, Damian C Genetos

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Wnt signaling is critical for skeletal development and homeostasis. Sclerostin (Sost) has emerged as a potent inhibitor of Wnt signaling and, thereby, bone formation. Thus, strategies to reduce sclerostin expression may be used to treat osteoporosis or non-union fractures. Transforming growth factor-beta (TGF-β) elicits various effects upon the skeleton both in vitro and in vivo depending on the duration and timing of administration. In vitro and in vivo studies demonstrate that TGF-β increases osteoprogenitor differentiation but decreases matrix mineralization of committed osteoblasts. Because sclerostin decreases matrix mineralization, this study aimed to examine whether TGF-β achieves such inhibitory effects via transcriptional modulation of Sost. Using the UMR106.01 mature osteoblast cell line, we demonstrated that TGF-βTGF-β 123 and Activin A increase Sost transcript expression. Pharmacologic inhibition of Alk4/5/7 in vitro and in vivo decreased endogenous Sost expression, and siRNA against Alk4 and Alk5 demonstrated their requirement for endogenous Sost expression. TGF-β 1 targeted the Sost bone enhancer ECR5 and did not affect the transcriptional activity of the endogenous Sost promoter. These results indicate that TGF-β 1 controls Sost transcription in mature osteoblasts, suggesting that sclerostin may mediate the inhibitory effect of TGF-β upon osteoblast differentiation.

Original languageEnglish (US)
Pages (from-to)663-669
Number of pages7
JournalBone
Volume50
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Transforming Growth Factor beta
Osteoblasts
Inhibin-beta Subunits
Osteogenesis
Skeleton
Small Interfering RNA
Osteoporosis
Homeostasis
Bone and Bones
Cell Line
In Vitro Techniques

Keywords

  • Bone
  • ECR5
  • Osteoblast
  • Sost
  • Transforming growth factor-beta
  • Wnt

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Loots, G. G., Keller, H., Leupin, O., Murugesh, D., Collette, N. M., & Genetos, D. C. (2012). TGF-β regulates sclerostin expression via the ECR5 enhancer. Bone, 50(3), 663-669. https://doi.org/10.1016/j.bone.2011.11.016

TGF-β regulates sclerostin expression via the ECR5 enhancer. / Loots, Gabriela G.; Keller, Hansjoerg; Leupin, Olivier; Murugesh, Deepa; Collette, Nicole M.; Genetos, Damian C.

In: Bone, Vol. 50, No. 3, 03.2012, p. 663-669.

Research output: Contribution to journalArticle

Loots, GG, Keller, H, Leupin, O, Murugesh, D, Collette, NM & Genetos, DC 2012, 'TGF-β regulates sclerostin expression via the ECR5 enhancer', Bone, vol. 50, no. 3, pp. 663-669. https://doi.org/10.1016/j.bone.2011.11.016
Loots GG, Keller H, Leupin O, Murugesh D, Collette NM, Genetos DC. TGF-β regulates sclerostin expression via the ECR5 enhancer. Bone. 2012 Mar;50(3):663-669. https://doi.org/10.1016/j.bone.2011.11.016
Loots, Gabriela G. ; Keller, Hansjoerg ; Leupin, Olivier ; Murugesh, Deepa ; Collette, Nicole M. ; Genetos, Damian C. / TGF-β regulates sclerostin expression via the ECR5 enhancer. In: Bone. 2012 ; Vol. 50, No. 3. pp. 663-669.
@article{4a1886cdf1ba41f082505472c570bc3c,
title = "TGF-β regulates sclerostin expression via the ECR5 enhancer",
abstract = "Wnt signaling is critical for skeletal development and homeostasis. Sclerostin (Sost) has emerged as a potent inhibitor of Wnt signaling and, thereby, bone formation. Thus, strategies to reduce sclerostin expression may be used to treat osteoporosis or non-union fractures. Transforming growth factor-beta (TGF-β) elicits various effects upon the skeleton both in vitro and in vivo depending on the duration and timing of administration. In vitro and in vivo studies demonstrate that TGF-β increases osteoprogenitor differentiation but decreases matrix mineralization of committed osteoblasts. Because sclerostin decreases matrix mineralization, this study aimed to examine whether TGF-β achieves such inhibitory effects via transcriptional modulation of Sost. Using the UMR106.01 mature osteoblast cell line, we demonstrated that TGF-βTGF-β 1-β 2-β 3 and Activin A increase Sost transcript expression. Pharmacologic inhibition of Alk4/5/7 in vitro and in vivo decreased endogenous Sost expression, and siRNA against Alk4 and Alk5 demonstrated their requirement for endogenous Sost expression. TGF-β 1 targeted the Sost bone enhancer ECR5 and did not affect the transcriptional activity of the endogenous Sost promoter. These results indicate that TGF-β 1 controls Sost transcription in mature osteoblasts, suggesting that sclerostin may mediate the inhibitory effect of TGF-β upon osteoblast differentiation.",
keywords = "Bone, ECR5, Osteoblast, Sost, Transforming growth factor-beta, Wnt",
author = "Loots, {Gabriela G.} and Hansjoerg Keller and Olivier Leupin and Deepa Murugesh and Collette, {Nicole M.} and Genetos, {Damian C}",
year = "2012",
month = "3",
doi = "10.1016/j.bone.2011.11.016",
language = "English (US)",
volume = "50",
pages = "663--669",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - TGF-β regulates sclerostin expression via the ECR5 enhancer

AU - Loots, Gabriela G.

AU - Keller, Hansjoerg

AU - Leupin, Olivier

AU - Murugesh, Deepa

AU - Collette, Nicole M.

AU - Genetos, Damian C

PY - 2012/3

Y1 - 2012/3

N2 - Wnt signaling is critical for skeletal development and homeostasis. Sclerostin (Sost) has emerged as a potent inhibitor of Wnt signaling and, thereby, bone formation. Thus, strategies to reduce sclerostin expression may be used to treat osteoporosis or non-union fractures. Transforming growth factor-beta (TGF-β) elicits various effects upon the skeleton both in vitro and in vivo depending on the duration and timing of administration. In vitro and in vivo studies demonstrate that TGF-β increases osteoprogenitor differentiation but decreases matrix mineralization of committed osteoblasts. Because sclerostin decreases matrix mineralization, this study aimed to examine whether TGF-β achieves such inhibitory effects via transcriptional modulation of Sost. Using the UMR106.01 mature osteoblast cell line, we demonstrated that TGF-βTGF-β 1-β 2-β 3 and Activin A increase Sost transcript expression. Pharmacologic inhibition of Alk4/5/7 in vitro and in vivo decreased endogenous Sost expression, and siRNA against Alk4 and Alk5 demonstrated their requirement for endogenous Sost expression. TGF-β 1 targeted the Sost bone enhancer ECR5 and did not affect the transcriptional activity of the endogenous Sost promoter. These results indicate that TGF-β 1 controls Sost transcription in mature osteoblasts, suggesting that sclerostin may mediate the inhibitory effect of TGF-β upon osteoblast differentiation.

AB - Wnt signaling is critical for skeletal development and homeostasis. Sclerostin (Sost) has emerged as a potent inhibitor of Wnt signaling and, thereby, bone formation. Thus, strategies to reduce sclerostin expression may be used to treat osteoporosis or non-union fractures. Transforming growth factor-beta (TGF-β) elicits various effects upon the skeleton both in vitro and in vivo depending on the duration and timing of administration. In vitro and in vivo studies demonstrate that TGF-β increases osteoprogenitor differentiation but decreases matrix mineralization of committed osteoblasts. Because sclerostin decreases matrix mineralization, this study aimed to examine whether TGF-β achieves such inhibitory effects via transcriptional modulation of Sost. Using the UMR106.01 mature osteoblast cell line, we demonstrated that TGF-βTGF-β 1-β 2-β 3 and Activin A increase Sost transcript expression. Pharmacologic inhibition of Alk4/5/7 in vitro and in vivo decreased endogenous Sost expression, and siRNA against Alk4 and Alk5 demonstrated their requirement for endogenous Sost expression. TGF-β 1 targeted the Sost bone enhancer ECR5 and did not affect the transcriptional activity of the endogenous Sost promoter. These results indicate that TGF-β 1 controls Sost transcription in mature osteoblasts, suggesting that sclerostin may mediate the inhibitory effect of TGF-β upon osteoblast differentiation.

KW - Bone

KW - ECR5

KW - Osteoblast

KW - Sost

KW - Transforming growth factor-beta

KW - Wnt

UR - http://www.scopus.com/inward/record.url?scp=84856973218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856973218&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2011.11.016

DO - 10.1016/j.bone.2011.11.016

M3 - Article

C2 - 22155511

AN - SCOPUS:84856973218

VL - 50

SP - 663

EP - 669

JO - Bone

JF - Bone

SN - 8756-3282

IS - 3

ER -